OncoMatch/Clinical Trials/NCT06929936
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
Is NCT06929936 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Trilaciclib combined with Docetaxel for non-small cell lung cancer.
Treatment: Trilaciclib combined with Docetaxel — This study is a prospective, single arm phase II study aimed at patients with locally advanced or metastatic non-small cell lung cancer undergoing second-line or beyond treatment. The aim is to evaluate the bone marrow protective effect of trilaciclib before docetaxel chemotherapy for locally advanced or metastatic NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR wild-type
Patients with negative driver genes must have received first line standard treatment (chemotherapy combined with immunotherapy).
Required: EGFR exon 19 deletion
EGFR (including 19del, L858R, S768I, L861Q, and/or G719X)
Required: EGFR L858R
EGFR (including 19del, L858R, S768I, L861Q, and/or G719X)
Required: EGFR S768I
EGFR (including 19del, L858R, S768I, L861Q, and/or G719X)
Required: EGFR L861Q
EGFR (including 19del, L858R, S768I, L861Q, and/or G719X)
Required: EGFR G719X
EGFR (including 19del, L858R, S768I, L861Q, and/or G719X)
Required: BRAF V600E
BRAF V600E
Required: NTRK1 fusion
NTRK
Required: NTRK2 fusion
NTRK
Required: NTRK3 fusion
NTRK
Required: MET exon 14 skipping mutation
MET14 exon skipping mutation
Required: RET fusion
RET
Required: ROS1 fusion
ROS1
Disease stage
Required: Stage IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy combined with immunotherapy — first line
Patients with negative driver genes must have received first line standard treatment (chemotherapy combined with immunotherapy).
Must have received: chemotherapy — after standard targeted therapy has failed
Patients with positive driver genes must have received at least one line chemotherapy after standard targeted therapy has failed.
Cannot have received: taxane (docetaxel)
Previously received treatment with docetaxel
Lab requirements
Blood counts
Hemoglobin ≥ 100 g/L (female), 110g/L (male); Neutrophil count ≥ 2×10^9/L; Platelet count ≥ 100×10^9/L
Kidney function
Creatinine ≤15mg/L or creatinine clearance rate (CrCl) ≥ 60mL/min (Cockcroft Gault formula)
Liver function
Total bilirubin ≤ 1.5x ULN; ALT and AST ≤ 3×ULN or ≤ 5×ULN (for patients with liver metastases); Albumin ≥ 30 g/L
Cardiac function
QTcF interval must be ≤ 480 ms (≤ 500 ms for patients with ventricular pacemakers)
Hemoglobin ≥ 100 g/L (female), 110g/L (male); Neutrophil count ≥ 2×10^9/L; Platelet count ≥ 100×10^9/L; Creatinine ≤15mg/L or creatinine clearance rate (CrCl) ≥ 60mL/min (Cockcroft Gault formula); Total bilirubin ≤ 1.5x ULN; ALT and AST ≤ 3×ULN or ≤ 5×ULN (for patients with liver metastases); Albumin ≥ 30 g/L; QTcF interval must be ≤ 480 ms (≤ 500 ms for patients with ventricular pacemakers)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify